66131-77-9

Basic information

• Product Name: 3-HYDROXY-6-PHENYLPYRIDINE
• Synonyms: 3-HYDROXY-6-PHENYLPYRIDINE;6-PHENYLPYRIDINE-3-OL;3-Hydroxu-6-phenylpyridine;5-Hydroxy-2-phenylpyridine;6-Phenylpyridin-3-ol
• CAS NO: 66131-77-9
• Molecular Formula: C₁₁H₉NO
• Molecular Weight: 171.2
• Mol File: 66131-77-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 393.3 °C at 760 mmHg
• Flash Point: 191.7 °C
• Appearance: /
• Density: 1.169 g/cm³
• Vapor Pressure: 9.46E-07mmHg at 25°C
• Refractive Index: 1.611
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-HYDROXY-6-PHENYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-HYDROXY-6-PHENYLPYRIDINE(66131-77-9)
• EPA Substance Registry System: 3-HYDROXY-6-PHENYLPYRIDINE(66131-77-9)

Safety Data

• Hazardous Substances Data: 66131-77-9(Hazardous Substances Data)

Usage

General Description

3-Hydroxy-6-Phenylpyridine is a chemical compound that contains a pyridine ring with a hydroxyl group and a phenyl group attached to it. It is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. The compound is also known for its potential application in the treatment of neurological disorders and is being studied for its neuroprotective and anti-inflammatory properties. Additionally, 3-Hydroxy-6-Phenylpyridine has been investigated for its potential use in the development of novel materials and as a building block in organic synthesis.

InChI:InChI=1/C11H9NO/c13-10-6-7-11(12-8-10)9-4-2-1-3-5-9/h1-8,13H

Upstream product

• 55717-45-8 6-bromo-pyridin-3-ol 
• 98-80-6 phenylboronic acid 
• 104704-63-4 3-benzyloxycarbonyl-4-phenyl-3-aza-7-oxatricyclo<4.1.0.0^2.5>heptane 
• 104704-57-6 2-benzyloxycarbonyl-3-phenyl-2-azabicyclo<2.2.0>hexa-5-ene 
• 113730-70-4 7-Phenyl-3-oxa-6-aza-tricyclo[3.2.0.0^2,4]heptane 
• 106895-31-2 7-Phenyl-3-oxa-6-aza-tricyclo[3.2.0.0^2,4]hept-6-ene 
• 106895-34-5 5-Phenyl-[1,4]oxazepine 

Relevant articles and documents

INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS

The present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers.

COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES

Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject is also provided.

Contrasting Anticancer Activity of Half-Sandwich Iridium(III) Complexes Bearing Functionally Diverse 2-Phenylpyridine Ligands

We report the synthesis, characterization, and antiproliferative activity of 15 iridium(III) half-sandwich complexes of the type [(η5-Cp?)Ir(2-(R′-phenyl)-R-pyridine)Cl] bearing either an electron-donating (-OH, -CH2OH, -CH3) or electron-withdrawing (-F, -CHO, -NO2) group at various positions on the 2-phenylpyridine (2-PhPy) chelating ligand giving rise to six sets of structural isomers. The X-ray crystal structures of [(η5-Cp?)Ir(2-(2′-fluorophenyl)pyridine)Cl] (1) and [(η5-Cp?)Ir(2-(4′-fluorophenyl)pyridine)Cl] (2) exhibit the expected "piano-stool" configuration. DFT calculations showed that substituents caused only localized effects on the electrostatic potential surface of the chelating 2-PhPy ligand of the complexes. Hydrolysis of all complexes is rapid, but readily reversed by addition of NaCl. The complexes show preferential binding to 9-ethylguanine over 9-methyladenine and are active catalysts for the oxidation of NADH to NAD+. Antiproliferative activity experiments in A2780 ovarian, MCF-7 breast, A549 lung, and HCT116 colon cancer cell lines showed IC50 values ranging from 1 to 89 μM, with the most potent complex, [(η5-Cp?)Ir(2-(2′-methylphenyl)pyridine)Cl] (13) (A2780 IC50 = 1.18 μM), being 10× more active than the parent, [(η5-Cp?)Ir(2-phenylpyridine)Cl], and 2× more active than [(η5-CpxPh)Ir(2-phenylpyridine)Cl]. Intriguingly, contrasting biological activities are observed between structural isomers despite exhibiting similar chemical reactivity. For pairs of structural isomers both the nature and position of the functional group can affect the hydrophobicity of the complex. An increase in hydrophobicity resulted in enhanced cellular-iridium accumulation in A2780 ovarian cells, which generally gave rise to an increase in potency. The structural isomers [(η5-Cp?)Ir(2-(4′-fluorophenyl)pyridine)Cl] (2) and [(η5-Cp?)Ir(2-phenyl-5-fluoropyridine)Cl] (4) preferentially localized in the cytosol > membrane and particulate > nucleus > cytoskeleton. This work highlights the strong dependence of biological behavior on the nature and position of the substituent on the chelating ligand and shows how this class of organometallic anticancer complexes can be fine-tuned to increase their potency without using extended cyclopentadienyl systems. (Chemical Equation Presented).